Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB3 | Q16875 | 7/20 | 0.41 |
| ▸ | PFKFB4 | Q16877 | 7/20 | 0.41 |
| ▸ | CMA1 | P23946 | 6/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3691229 | 0.92 | PFKFB3 (0.42) | PFKFB3PFKFB4CMA1HTR6NPSR1 | |
| SCHEMBL3689242 | 0.90 | PPARD (0.43) | PFKFB3PFKFB4CMA1PPARDL3MBTL1 | |
| SCHEMBL3692915 | 0.90 | PPARD (0.45) | PFKFB3PFKFB4CMA1PPARDAKR1B1 | |
| SCHEMBL3684015 | 0.90 | PFKFB3 (0.40) | PFKFB3PFKFB4CMA1PPARDHTR6 | |
| SCHEMBL3679501 | 0.88 | PTGDR2 (0.39) | PFKFB3PFKFB4CMA1PPARDHTR6 | |
| SCHEMBL3687426 | 0.87 | PTGDR2 (0.41) | PFKFB3PFKFB4CMA1PPARDPTPN1 | |
| SCHEMBL3687141 | 0.86 | PTGIR (0.44) | PFKFB3PFKFB4CMA1HTR6PTPN1 | |
| SCHEMBL3683608 | 0.86 | PPARD (0.44) | PFKFB3PFKFB4PPARD | |
| SCHEMBL3684240 | 0.86 | PPARD (0.44) | PFKFB3PFKFB4CMA1PPARD | |
| SCHEMBL3686669 | 0.85 | PPARD (0.43) | PFKFB3PFKFB4CMA1PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | claimed |
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | ELI LILLY AND COMPANY (US) | 2006-09-28 | — | — | US | claimed |
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| EP-1597248-B1 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | LILLY CO ELI (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1597248-B1 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | LILLY CO ELI (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | ELI LILLY AND COMPANY (US) | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | PPARD, PPARA, PPARG | PFKFB3 507/4885PFKFB4 469/4885CMA1 4529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.